| P2093 | author name string | Leonard Sender | |
| | Keri B Zabokrtsky | |
| P2860 | cites work | Impact of socioeconomic status and sociodemographic factors on melanoma presentation among ethnic minorities. | Q37436793 |
| | Opening end-of-life discussions: how to introduce Voicing My CHOiCES™, an advance care planning guide for adolescents and young adults | Q37505696 |
| | Racial/ethnic differences in clinical trial enrollment, refusal rates, ineligibility, and reasons for decline among patients at sites in the National Cancer Institute's Community Cancer Centers Program. | Q37626917 |
| | A Qualitative Study of Phase III Cancer Clinical Trial Enrollment Decision-Making: Perspectives from Adolescents, Young Adults, Caregivers, and Providers | Q37640494 |
| | Attitudes Toward Cancer Clinical Trial Participation in Young Adults with a History of Cancer and a Healthy College Student Sample: A Preliminary Investigation | Q37640500 |
| | Impact of breast cancer subtypes on 3-year survival among adolescent and young adult women | Q37690054 |
| | CD19-CAR trials | Q37692134 |
| | Comparison of survival outcomes among cancer patients treated in and out of clinical trials | Q37696455 |
| | BRAF and beyond: Tailoring strategies for the individual melanoma patient | Q37702515 |
| | BRAF as therapeutic target in melanoma | Q37720832 |
| | Adolescent and Young Adult Oncology Training for Health Professionals: A Position Statement | Q37786144 |
| | Quality Cancer Care for Adolescents and Young Adults: A Position Statement | Q37790555 |
| | BRAFV600E: implications for carcinogenesis and molecular therapy | Q37851238 |
| | Philadelphia chromosome-positive acute lymphoblastic leukemia: current treatment and future perspectives | Q37862648 |
| | Tyrosine kinase inhibitor use in pediatric Philadelphia chromosome-positive acute lymphoblastic anemia | Q37967302 |
| | Recent advances in pathway-targeted cancer drug therapies emerging from cancer genome analysis | Q37982906 |
| | Efficacy and safety of adoptive immunotherapy using anti-CD19 chimeric antigen receptor transduced T-cells: a systematic review of phase I clinical trials | Q38035043 |
| | Whole genome and exome sequencing of melanoma: a step toward personalized targeted therapy | Q38041731 |
| | Adult lymphoblastic lymphoma | Q38046048 |
| | The molecular basis of T cell acute lymphoblastic leukemia | Q38047834 |
| | The adolescent and young adult with cancer: state of the art -- psychosocial aspects | Q38108734 |
| | Biology and treatment of acute lymphocytic leukemia in adolescents and young adults | Q38110061 |
| | Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma | Q24597152 |
| | Cutaneous melanoma attributable to sunbed use: systematic review and meta-analysis | Q24629925 |
| | Treating childhood acute lymphoblastic leukemia without cranial irradiation | Q24644599 |
| | Discovery of the Philadelphia chromosome: a personal perspective | Q24683696 |
| | Developing strategies in the immunotherapy of leukemias | Q26996310 |
| | Neurogenesis, exercise, and cognitive late effects of pediatric radiotherapy | Q27002694 |
| | Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma | Q27852990 |
| | Inhibition of Mutated, Activated BRAF in Metastatic Melanoma | Q27860458 |
| | Cancer statistics, 2014 | Q27861018 |
| | Improved Survival with Ipilimumab in Patients with Metastatic Melanoma | Q27861062 |
| | The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma | Q28088496 |
| | Indoor tanning and risk of melanoma: a case-control study in a highly exposed population | Q28396134 |
| | Novel susceptibility variants at 10p12.31-12.2 for childhood acute lymphoblastic leukemia in ethnically diverse populations | Q28943485 |
| | Emerging adulthood: A theory of development from the late teens through the twenties. | Q29393914 |
| | Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia | Q29617590 |
| | Chimeric antigen receptor-modified T cells for acute lymphoid leukemia | Q29620130 |
| | CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia | Q29620607 |
| | Knowledge, attitudes, and self-efficacy as predictors of preparedness for oncology clinical trials: a mediational model | Q30219015 |
| | Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434 | Q30300395 |
| | Adolescent perspectives on phase I cancer research | Q30531481 |
| | The National Cancer Institute-American Society of Clinical Oncology Cancer Trial Accrual Symposium: summary and recommendations | Q30557206 |
| | Early diagnosis of cutaneous melanoma: revisiting the ABCD criteria | Q31134783 |
| | Melanoma in pediatric, adolescent, and young adult patients | Q33554622 |
| | Clinical trial awareness among racial/ethnic minorities in HINTS 2007: sociodemographic, attitudinal, and knowledge correlates | Q33581488 |
| | A unique gender difference in early onset melanoma implies that in addition to ultraviolet light exposure other causative factors are important | Q33637973 |
| | Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor acute lymphoblastic leukemia | Q33680280 |
| | A Diversified Recruitment Approach Incorporating Social Media Leads to Research Participation Among Young Adult-Aged Female Cancer Survivors | Q33724479 |
| | Evaluating melanoma drug response and therapeutic escape with quantitative proteomics | Q33850665 |
| | Targeting the PD-1 pathway: a promising future for the treatment of melanoma. | Q33946513 |
| | Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia | Q33985127 |
| | BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells | Q34011519 |
| | FDA drug approval summary: nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia/lymphoma | Q34012525 |
| | Indoor ultraviolet tanning and skin cancer: health risks and opportunities | Q34018094 |
| | Reduced melanoma after regular sunscreen use: randomized trial follow-up | Q34024931 |
| | Clinical trial participation and time to treatment among adolescents and young adults with cancer: does age at diagnosis or insurance make a difference? | Q34028600 |
| | Malignant melanoma: prevention, early detection, and treatment in the 21st century | Q34032933 |
| | Risk of late effects of treatment in children newly diagnosed with standard-risk acute lymphoblastic leukaemia: a report from the Childhood Cancer Survivor Study cohort | Q34079996 |
| | NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas | Q34102089 |
| | Transition of care for young adult survivors of childhood and adolescent cancer: rationale and approaches | Q34107335 |
| | Awareness of the risks of tanning lamps does not influence behavior among college students | Q34153939 |
| | Outcomes of children with BCR-ABL1–like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease | Q34172033 |
| | Understanding the functional late effects and informational needs of adult survivors of childhood cancer | Q34182587 |
| | ARID5B genetic polymorphisms contribute to racial disparities in the incidence and treatment outcome of childhood acute lymphoblastic leukemia | Q34250780 |
| | Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia | Q34314927 |
| | Cancer incidence among adolescents and young adults in urban Shanghai, 1973-2005 | Q34374429 |
| | Targeting signaling pathways in acute lymphoblastic leukemia: new insights | Q34390600 |
| | Childhood and adolescent cancer statistics, 2014. | Q34401667 |
| | Sunscreens: a review of health benefits, regulations, and controversies | Q34422627 |
| | Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies | Q34443923 |
| | Canadian adolescents and young adults with cancer: opportunity to improve coordination and level of care | Q34590009 |
| | The role of BRAF V600 mutation in melanoma | Q34637951 |
| | Improved prognosis for older adolescents with acute lymphoblastic leukemia. | Q34679298 |
| | Melanoma incidence trends and survival in adolescents and young adults in Queensland, Australia. | Q34776157 |
| | Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group study AALL0031. | Q34810036 |
| | Unique characteristics of adolescent and young adult acute lymphoblastic leukemia, breast cancer, and colon cancer | Q34820332 |
| | Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid | Q34853520 |
| | Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab | Q34981971 |
| | Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia | Q35015010 |
| | American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes | Q35123157 |
| | Attitudinal barriers to participation in oncology clinical trials: factor analysis and correlates of barriers | Q35563968 |
| | Melanoma in adolescents and young adults (ages 15-39 years): United States, 1999-2006. | Q35661725 |
| | Adaptive upregulation of FOXD3 and resistance to PLX4032/4720-induced cell death in mutant B-RAF melanoma cells | Q35683271 |
| | Engaging referring physicians in the clinical trial process | Q35695955 |
| | Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome | Q35876592 |
| | Correlates of intentional tanning among adolescents in the United States: a systematic review of the literature | Q35962464 |
| | Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group | Q36058255 |
| | T-cell adoptive immunotherapy for acute lymphoblastic leukemia | Q38169656 |
| | Novel antibody therapy in acute lymphoblastic leukemia | Q38195539 |
| | Current therapy for malignant melanoma. | Q38198203 |
| | Assessing quality of life in young adult cancer survivors: development of the Survivorship-Related Quality of Life scale | Q38204309 |
| | Vemurafenib | Q38206457 |
| | Melanoma m1: diagnosis and therapy | Q38210817 |
| | National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network | Q38214265 |
| | Increasing the number of clinical trials available to adolescents diagnosed with cancer. | Q38219433 |
| | Clinical trial enrollment among adolescents with cancer: supplement overview | Q38219434 |
| | Understanding and addressing the lack of clinical trial enrollment among adolescents with cancer | Q38219436 |
| | Available, accessible, aware, appropriate, and acceptable: a strategy to improve participation of teenagers and young adults in cancer trials | Q38225681 |
| | The evolution of checkpoint blockade as a cancer therapy: what's here, what's next? | Q38332778 |
| | The Role of Anti-PD-1/PD-L1 Agents in Melanoma: Progress to Date | Q38388590 |
| | Legally brown: using ethnographic methods to understand sun protection attitudes and behaviours among young Australians 'I didn't mean to get burnt--it just happened!' | Q38550195 |
| | The clinical diagnosis of early malignant melanoma: expansion of the ABCD criteria to improve diagnostic sensitivity | Q38554408 |
| | Efficacy of intermittent combined RAF and MEK inhibition in a patient with concurrent BRAF- and NRAS-mutant malignancies | Q39019022 |
| | Psychological distress and unsatisfied need for psychosocial support in adolescent and young adult cancer patients during the first year following diagnosis | Q39263441 |
| | Treatment of chronic myelogenous leukemia as a paradigm for solid tumors: how targeted agents in newly diagnosed disease transformed outcomes | Q39669855 |
| | National Cancer Research Institute Teenage and Young Adult Clinical Studies Group: The United Kingdom Approach to Research. International Perspectives on AYAO, Part 4. | Q40059987 |
| | Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia | Q40101776 |
| | Philadelphia chromosome positive childhood acute lymphoblastic leukemia. | Q40276532 |
| | Uninsurance and health care access among young adults in the United States | Q40408446 |
| | Improved clinical trial enrollment in adolescent and young adult (AYA) oncology patients after the establishment of an AYA oncology program uniting pediatric and medical oncology divisions | Q42630817 |
| | The reality of hospitalisation: stories from family members of their hospital experience for adolescents and young adults living with and dying from cancer | Q42658153 |
| | Adolescents and young adults with a "rare" cancer: getting past semantics to optimal care for patients with germ cell tumors | Q42716527 |
| | BRAF targeted therapy changes the treatment paradigm in melanoma | Q42733647 |
| | Philadelphia chromosome-positive acute lymphoblastic leukemia in childhood | Q42769654 |
| | Meeting reality: young adult cancer survivors' experiences of reentering everyday life after cancer treatment | Q43596944 |
| | Health problems in survivors of childhood cancer: the need for international collaboration in long-term follow-up care | Q43667690 |
| | Prevalence and predictors of post-traumatic stress symptoms in adolescent and young adult cancer survivors: a 1-year follow-up study | Q43896358 |
| | Vocational identity, positive affect, and career thoughts in a group of young adult central nervous system cancer survivors | Q44359574 |
| | Skin self-examination and the ABCDE rule in the early diagnosis of melanoma: is the game over? | Q44423844 |
| | Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia | Q44473547 |
| | Pediatric melanoma: results of a large cohort study and proposal for modified ABCD detection criteria for children | Q44771769 |
| | Delay in surgical treatment and survival after breast cancer diagnosis in young women by race/ethnicity | Q44775873 |
| | Psychosocial challenges and resource needs of young adult cancer survivors: implications for program development | Q44914181 |
| | How I treat nodular lymphocyte predominant Hodgkin lymphoma | Q44924928 |
| | IGH@ translocations, CRLF2 deregulation, and microdeletions in adolescents and adults with acute lymphoblastic leukemia | Q45022613 |
| | Social problem solving and social performance after a group social skills intervention for childhood brain tumor survivors | Q45891253 |
| | Psychosocial service use and unmet need among recently diagnosed adolescent and young adult cancer patients. | Q45918388 |
| | Estimating the health and economic burden of cancer among those diagnosed as adolescents and young adults | Q36092297 |
| | Children's Oncology Group's 2013 blueprint for research: adolescent and young adult oncology | Q36157250 |
| | Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study. | Q36182008 |
| | Executive functions and social skills in survivors of pediatric brain tumor | Q36296007 |
| | Late effects of total body irradiation and hematopoietic stem cell transplant in children under 3 years of age. | Q36369196 |
| | Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies | Q36386891 |
| | Childhood Cancer Survivor Study participants' perceptions and knowledge of health insurance coverage: implications for the Affordable Care Act | Q36447240 |
| | Barriers to cancer clinical trial participation among American Indian and Alaska Native tribal college students | Q36515341 |
| | Patient income level and cancer clinical trial participation | Q36589626 |
| | Recent skin self-examination and doctor visits in relation to melanoma risk and tumour depth | Q36628513 |
| | The business case for provider participation in clinical trials research: an application to the National Cancer Institute's community clinical oncology program | Q36675653 |
| | When silence is not golden: Engaging adolescents and young adults in discussions around end-of-life care choices | Q36695652 |
| | Unmet Support Service Needs and Health-Related Quality of Life among Adolescents and Young Adults with Cancer: The AYA HOPE Study | Q36747319 |
| | Increasing and worsening late effects in childhood cancer survivors during follow-up. | Q36841132 |
| | What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies | Q36843677 |
| | Melanoma risk factors, perceived threat and intentional tanning: an international online survey | Q36902167 |
| | Cancer-specific outcomes among young adults without health insurance | Q36934277 |
| | Challenges in the recruitment of adolescents and young adults to cancer clinical trials | Q36961822 |
| | Cancer survival disparities by health insurance status | Q36977446 |
| | Health-related quality of life of adolescent and young adult patients with cancer in the United States: the Adolescent and Young Adult Health Outcomes and Patient Experience study | Q37065829 |
| | The distinctive biology of cancer in adolescents and young adults. | Q37114564 |
| | Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia | Q37172988 |
| | Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study | Q37263151 |
| | Initial experience with CMC-544 (inotuzumab ozogamicin) in pediatric patients with relapsed B-cell acute lymphoblastic leukemia | Q37296134 |
| | Interventions to improve neuropsychological functioning in childhood cancer survivors | Q37299475 |
| | Cytogenetics of paediatric and adolescent acute lymphoblastic leukaemia. | Q37324584 |
| | Recent developments in anti-cancer agents targeting the Ras/Raf/ MEK/ERK pathway. | Q37370630 |
| | Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation | Q37390239 |
| | Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study | Q37412290 |
| | Design and development of therapies using chimeric antigen receptor-expressing T cells | Q37418289 |
| | Trailblazers in Adolescent and Young Adult Oncology. | Q45933421 |
| | Family physician preferences and knowledge gaps regarding the care of adolescent and young adult survivors of childhood cancer. | Q45993891 |
| | Intervention format and delivery preferences among young adult cancer survivors. | Q46003683 |
| | Association between insurance and socioeconomic status and risk of advanced stage Hodgkin lymphoma in adolescents and young adults. | Q46006754 |
| | Increases in melanoma among adolescent girls and young women in California: trends by socioeconomic status and UV radiation exposure | Q46070468 |
| | The International Charter of Rights for Young People with Cancer | Q46085799 |
| | Deaths: leading causes for 2010. | Q46317951 |
| | Limitations in health care access and utilization among long-term survivors of adolescent and young adult cancer | Q46685866 |
| | Adolescents with acute lymphoblastic leukaemia: outcome on UK national paediatric (ALL97) and adult (UKALLXII/E2993) trials | Q46900601 |
| | Clinical trial discussion, referral, and recruitment: physician, patient, and system factors | Q46955911 |
| | Effectiveness of integrated multidisciplinary rehabilitation in primary brain cancer survivors in an Australian community cohort: a controlled clinical trial | Q47859625 |
| | Adolescent and young adult oncology. Clinical practice guidelines in oncology | Q48615937 |
| | Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial | Q49322866 |
| | Decision-making by adolescents and parents of children with cancer regarding health research participation. | Q50732271 |
| | Proportion of lifetime UV dose received by children, teenagers and adults based on time-stamped personal dosimetry. | Q50753927 |
| | The new national cancer institute national clinical trials network. | Q50980749 |
| | Adolescents and young adults with cancer: the scope of the problem and criticality of clinical trials. | Q53231062 |
| | Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. | Q54372714 |
| | Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma. | Q54480523 |
| | ENCCA WP17-WP7 consensus paper on teenagers and young adults (TYA) with bone sarcomas | Q56973339 |
| | Sun Safety Knowledge, Attitudes, and Behaviors Among Beachgoing Adolescents | Q58286122 |
| | Adolescents in Clinical Trials | Q58392299 |
| | A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia | Q59080605 |
| | Unmet needs in cancer rehabilitation during the early cancer trajectory – a nationwide patient survey | Q59256867 |
| | Differences in outcome in adolescents with acute lymphoblastic leukemia: a consequence of better regimens? Better doctors? Both? | Q73063048 |
| | Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials | Q73063060 |
| | Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia | Q73448999 |
| | Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in the Netherlands | Q80860639 |
| | Targeting mutant BRAF in metastatic melanoma | Q82213660 |
| | Epidemiology of melanoma | Q83323199 |
| | Metastatic melanoma: results of 'classical' second-line treatment with cytotoxic chemotherapies | Q84221196 |
| | Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with post-transplant relapsed acute lymphoblastic leukemia | Q85190963 |
| | Assessing information and service needs of young adults with cancer at a single institution: the importance of information on cancer diagnosis, fertility preservation, diet, and exercise | Q86630786 |
| | Regulatory barriers to clinical trial enrollment of adolescent and young adult oncology patients | Q88057514 |
| | The malignant melanoma landscape | Q88189060 |
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | teenager | Q1492760 |
| P304 | page(s) | 465-480 | |
| P577 | publication date | 2015-05-26 | |
| P1433 | published in | Nature Reviews Clinical Oncology | Q641640 |
| P1476 | title | Adolescent and young adult patients with cancer: a milieu of unique features | |
| P478 | volume | 12 | |